Charles River slides as divestiture-driven 2026 revenue haircut and rising short interest weigh
Charles River Laboratories shares fell about 3% Wednesday as investors continue repricing the company after its February portfolio reshaping and divestiture agreements, which are expected to cut 2026 reported revenue by a little over $200 million. Bearish positioning has also risen, with short interest reaching about 9.4% of shares as of March 31.
1) What’s moving the stock
Charles River Laboratories (CRL) is trading lower today as investors continue to digest the company’s strategic reshaping and the near-term revenue headwind tied to planned divestitures. A key overhang is management’s expectation that the divestitures will reduce 2026 reported revenue by slightly more than $200 million, which also mechanically trims organic growth by more than 50 basis points under the company’s framework. (sec.gov)
2) Why sentiment is still fragile
Beyond the revenue haircut, positioning has turned more cautious. Short interest rose to about 4.59 million shares as of March 31 (roughly 9.4% of shares), indicating elevated bearish bets that can amplify day-to-day declines when the tape weakens. (marketbeat.com)
3) The backdrop: last guidance and what investors are debating
CRL’s latest full-year guide (issued with Q4/FY 2025 results on February 18, 2026) frames 2026 as a stabilization-and-execution year after a period of uneven demand and segment-level pressure, including continued challenges in CDMO. Investors are weighing whether a streamlined portfolio and efficiency actions can lift profitability fast enough to offset the divestiture-related reduction in revenue and any ongoing softness in outsourcing demand. (charlesriverlaboratories.gcs-web.com)